Advert for Healthcare Professionals Only
I am a patient (Please go to our patient website)
- All Topics
- Allergy and Clinical Immunology
- Anesthesiology
- Angiology
- Cardiology
- Central Nervous System
- Clinical Laboratory
- Complementary and Alternative Medicine
- Critical Care/Intensive Care
- Dermatology
- Diabetes and Endocrinology
- Ear, Nose and Throat
- Emergency Medicine
- Eye Health and Disorders
- Family Medicine
- Gastroenterology
- Gerontology/Geriatrics
- Haematology
- Hepatology
- HIV/AIDS
- Immunology
- Infectious Diseases
- Internal Medicine
- Kidney and Urological Diseases
- Medical Genetics
- Men's Health, Andrology and Urology
- Musculoskeletal Disorders
- Neonatal/Perinatal Medicine
- Neurological Disorders
- Nutrition and Dietetics
- Oncology
- Orthopaedics
- Paediatrics
- Pain Management
- Palliative Medicine
- Plastic Surgery and Aesthetic Medicine
- Podiatry
- Preventive Medicine
- Psychiatry/Mental Health
- Radiology
- Respiratory
- Rheumatology
- Sexual Health
- Sleep Medicine
- Sports Medicine
- Surgery (General)
- Transplantation
- Tropical Medicine
- Vaccines
- Women's Health and Obs/Gyn
- ADHD
- Alzheimer's Disease
- Arthritis
- Atopic Dermatitis
- Cholesterol
- Chronic Myeloid Leukemia
- COPD
- Cystic Fibrosis
- Diabetes
- Gastrointestinal Stromal Tumours
- Hepatitis
- Hypertension
- Insomnia
- Lysosomal Storage Disorders
- Men's Health
- Multiple Sclerosis
- Niemann-Pick type C
- NSCLC
- Opioids and Pain
- Parkinson's Disease
- Post-Myocardial Infarction
- Prostate Cancer
- Renal Anaemia
- Renal Cell Carcinoma
- Soft Tissue Sarcoma
- Third Party Website - Asthma and COPD
- CAPOZIDE TABLETS
- SURMONTIL 10MG AND 25MG TABLETS
- NAPRATEC OP
- COBALIN-H INJECTION
- CARBEX
- CALCIUM RESONIUM 99.934% W/W POWDER FOR ORAL/RECTAL SUSPENSION
- HYPURIN BOVINE ISOPHANE
- HYPURIN BOVINE LENTE
- HYPURIN PORCINE 30/70 MIX CARTRIDGES
- HYPURIN BOVINE ISOPHANE VIALS
- DUKORAL ORAL CHOLERA VACCINE
- OXYNORM LIQUID 5 MG/5 ML ORAL SOLUTION
- DORZOLAMIDE/TIMOLOL EYE DROPS
- FENOFIBRATE 267MG CAPSULES
- TRACRIUM INJECTION
- EXOCIN
- FRAGMIN - TREATMENT OF VTE
- FLUDARABINE PHOSPHATE 50 MG POWDER FOR SOLUTION FOR INJECTION OR INFUSION
- GABITRIL FILM-COATED TABLETS (5 , 10, 15 MG)
- PROTOPIC 0.03% OINTMENT
- XISMOX 60 XL PROLONGED RELEASE TABLETS
- PALLADONE SR CAPSULES
- ZINERYT
- PURI-NETHOL 50 MG TABLETS
- DAKTACORT OINTMENT
- MYLERAN 2 MG FILM-COATED TABLETS
- NEOTIGASON 10MG CAPSULES
- LEUKERAN TABLETS 2 MG
- LANVIS TABLETS 40 MG
- PROVIGIL 100 MG TABLETS, PROVIGIL 200 MG TABLETS
- ADHD
- Alzheimers
- Anxiety Disorders
- Arthritis
- Asthma
- Avonex
- Breast Cancer
- Cervical Cancer
- Cholesterol
- Colorectal Cancer
- Copaxone
- Depression
- Diabetes
- Erectile Dysfunction
- Extavia
- Hypertension
- Insomnia
- Men's Health
- Meningitis
- Migraine
- Pain Management
- Parkinson's
- Pharma News
- Post-MI
- Pregnancy
- Prostate
- Rebif
- Renal anaemia
- Renal Cell Carcinoma
- Thrombosis
- Thromboembolism
- Tysabri
Advert for Healthcare Professionals Only
Latest Drugs
Gastroenterology Drug Data - A-Z (Espanol)
Drug Class Description
Suplementos de calcio con vitamina dDrug Description
EMULSIONPresentation
Oral. Adultos: usualmente 1 cucharada sopera (15 ml) cada 8 horas, preferentemente después de las comidas. Niños: 2 cucharaditas (10 ml) cada 8 horas. 15 ml equivalen a 100 mg de calcio elemento.Indications
Profilaxis y tratamiento de deficiencia de calcio: pacientes con dieta inadecuada, por lo general asociada a un aumento de la demanda (mujeres embarazadas y lactantes, ancianos, pre y postmenopausia, etc). Coadyuvante en la profilaxis y tratamiento de la osteoporosis.Contra Indications
Hipercalcemia o hipercalciuria.Special Precautions
En pacientes con insuficiencia renal hay mayor riesgo de hipercalcemia. Puede agravar la enfermedad en pacientes con cálculos renales de calcio. Realizar controles periódicos de la calcemia, especialmente durante tratamientos prolongados y en pacientes con insuficiencia renal.Interactions
- Bisfosfonatos (acido alendrónico, etc): hay estudios con sales de calcio por vía oral, en los que se ha registrado disminución en los niveles séricos de alendrónico, con posible inhibición de su efecto, por disminución de su absorción oral, como consecuencia de la formación de complejos no absorbibles. - Fenitoína: hay algún estudio en el que se ha registrado reducción de la absorción oral de fenitoína, con posible inhibición de su efecto, por formación de quelatos. Se recomienda espaciar la administración. - Levotiroxina: hay algún estudio en el que se ha registrado disminución de la efectividad de levotiroxina, por posible disminución de su absorción oral. - Sales de hierro (sulfato de hierro): hay algún estudio en el que se ha registrado disminución de la absorción de la sal de hierro, por posible formación de complejos poco solubles. - Sales de zinc (sulfato de zinc): hay un estudio en el que se ha registrado disminución del área bajo curva (72%) de la sal de zinc. No se conoce el mecanismo. Se recomienda espaciar la administración. - Tiazidas (hidroclorotiazida): hay algún estudio en el que se ha registrado hipercalcemia y alcalosis metabólica, debido a la disminución de la excreción de calcio causada por las tiazidas.Adverse Reactions
Excepcionalmente, molestias gastrointestinales: estreñimiento o diarrea. Los siguientes síntomas pueden ser indicativos de hipercalcemia: náuseas, vómitos, anorexia, dolor abdominal, dolor óseo, sed, poliuria, debilidad muscular, somnolencia o confusión.Manufacturer
MADARIAGADrug Availability
EXCLUIDA OFERTA SEGURIDAD SOCIALAdvert for Healthcare Professionals Only
Related News
FDA approves Remicade for Pediatric Ulcerative Colitis Gastroenterology Page
The FDA has approved Remicade (infliximab), from Janssen Biotech, for the treatment of moderately to severely active Ulcerative Colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy. The approval was supported by evidence from studies of Remicade in adults with Ulcerative Colitis plus additional data from a pivotal Phase III trial evaluating the efficacy and safety of Remicade in the treatment of pediatric patients. Results from the pediatric UC study presented in May 2011 showed that treatment with Remicade 5 mg/kg induced clinical response in 73 percent of patients at week 8 and demonstrated a safety profile consistent with previous clinical trials conducted in an adult population.
FDA approves anti-Helicobacter pylori antibody Gastroenterology Page
The FDA has given 510(K) approval to Ventana anti-Helicobacter pylori (SP48) Rabbit Monoclonal Primary Antibody (H. pylori), from Ventana Medical Systems. This antibody is the first H. pylori antibody to receive such clearance and when used in immunohistochemical staining, aids in the detection of Helicobacter pylori, a bacterium linked to Chronic Gastritis, Ulcers and Stomach Cancer. The antibody provides pathologists unprecedented views of the bacterium, allowing for a more accurate patient diagnosis and is also fully integrated with the Ventana BenchMark XT and BenchMark Ultra slide staining instruments.
Napo Pharma terminates agreement wit Salix Pharma for crofelemer for Chronic Diarrhoea in AIDS patients Gastroenterology Page
Napo Pharma has terminated its agreement with Salix Pharma for failure of Salix Pharma to proceed with an application to the FDA for crofelemer for chronic diarrhoea in people living with HIV/AIDS, despite a successful Phase III result. Napo has filed a lawsuit against Salix seeking $150 million for breach of contract.
